{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:45:51Z","timestamp":1785026751921,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Child and Adolescent Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.chc.2023.02.006","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T13:42:41Z","timestamp":1680010961000},"page":"573-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Advances in Pharmacotherapy for Pediatric Anxiety Disorders"],"prefix":"10.1016","volume":"32","author":[{"given":"Cassandra M.","family":"Nicotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.chc.2023.02.006_bib1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","article-title":"Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety","volume":"359","author":"Walkup","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chc.2023.02.006_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1753-2000-4-1","article-title":"Child\/adolescent anxiety multimodal study (CAMS): rationale, design, and methods","volume":"4","author":"Compton","year":"2010","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.janxdis.2010.01.009","article-title":"Clinical characteristics of anxiety disordered youth","volume":"24","author":"Kendall","year":"2010","journal-title":"J\u00a0Anxiety Disord"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib4","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m11415","article-title":"Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications","volume":"79","author":"Bushnell","year":"2018","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2023.02.006_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaac.2018.01.015","article-title":"The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis","volume":"57","author":"Strawn","year":"2018","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib6","doi-asserted-by":"crossref","first-page":"14375","DOI":"10.4088\/JCP.17r12064","article-title":"Efficacy and tolerability of pharmacotherapy for pediatric anxiety disorders: a network meta-analysis","volume":"80","author":"Dobson","year":"2019","journal-title":"The Journal of clinical psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2023.02.006_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","article-title":"Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities","volume":"167","author":"S\u00e1nchez","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.chc.2023.02.006_bib8","first-page":"209","article-title":"Escitalopram: a new SSRI for the treatment of depression in primary care","volume":"4","author":"Culpepper","year":"2002","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2023.02.006_bib9","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13396","article-title":"Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study","volume":"81","author":"Strawn","year":"2020","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/cap.2023.0004","article-title":"A multicenter double-blind, placebo-controlled trial of escitalopram in children and adolescents with Generalized Anxiety Disorder","volume":"33","author":"Strawn","year":"2023","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2023.02.006_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CHI.0000037049.04952.9F","article-title":"Fluoxetine for the treatment of childhood anxiety disorders","volume":"42","author":"Birmaher","year":"2003","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2023.02.006_bib12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/01.chi.0000183464.41777.c1","article-title":"Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial","volume":"44","author":"Clark","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2023.02.006_bib13","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/chi.0b013e318154bb57","article-title":"SET-C versus fluoxetine in the treatment of childhood social phobia","volume":"46","author":"Beidel","year":"2007","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2023.02.006_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00004583-199409000-00009","article-title":"Fluoxetine for childhood anxiety disorders","volume":"33","author":"Birmaher","year":"1994","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/cap.1997.7.17","article-title":"Open fluoxetine treatment of mixed anxiety disorders in children and adolescents","volume":"7","author":"Fairbanks","year":"1997","journal-title":"J Child Adolesc Psychopharmacol. Spring"},{"issue":"12","key":"10.1016\/j.chc.2023.02.006_bib16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1176\/appi.ajp.158.12.2008","article-title":"Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder","volume":"158","author":"Rynn","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2023.02.006_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00004583-200105000-00016","article-title":"Sertraline in children and adolescents with social anxiety disorder: an open trial","volume":"40","author":"Compton","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2023.02.006_bib18","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1037\/a0025933","article-title":"Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS","volume":"79","author":"Ginsburg","year":"2011","journal-title":"J\u00a0Consult Clin Psychol"},{"issue":"Pt A","key":"10.1016\/j.chc.2023.02.006_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jad.2021.10.047","article-title":"Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety","volume":"298","author":"Strawn","year":"2022","journal-title":"J\u00a0Affect Disord"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaac.2014.12.015","article-title":"Child\/Adolescent anxiety multimodal study: evaluating safety","volume":"54","author":"Rynn","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaac.2013.11.010","article-title":"24- and 36-week outcomes for the child\/adolescent anxiety multimodal study (CAMS)","volume":"53","author":"Piacentini","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"17","key":"10.1016\/j.chc.2023.02.006_bib22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"344","author":"Walkup","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/104454602760386879","article-title":"Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study","volume":"12","author":"Walkup","year":"2002","journal-title":"J Child Adolesc Psychopharmacol. Fall"},{"issue":"11","key":"10.1016\/j.chc.2023.02.006_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archpsyc.61.11.1153","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder","volume":"61","author":"Wagner","year":"2004","journal-title":"Arch Gen Psychiatr"},{"issue":"2","key":"10.1016\/j.chc.2023.02.006_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/ajp.2007.164.2.290","article-title":"Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials","volume":"164","author":"Rynn","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2023.02.006_bib26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.biopsych.2007.02.025","article-title":"A\u00a0randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder","volume":"62","author":"March","year":"2007","journal-title":"Biol Psychiatr"},{"issue":"4","key":"10.1016\/j.chc.2023.02.006_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaac.2015.01.008","article-title":"A\u00a0randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder","volume":"54","author":"Strawn","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2023.02.006_bib28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/chi.0b013e3180ca8385","article-title":"Atomoxetine treatment for pediatric patients with attention-deficit\/hyperactivity disorder with comorbid anxiety disorder","volume":"46","author":"Geller","year":"2007","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"key":"10.1016\/j.chc.2023.02.006_bib29","first-page":"1","article-title":"Pharmacologic predictors of benzodiazepine response trajectory in anxiety disorders: a Bayesian hierarchical modeling meta-analysis","author":"Stimpfl","year":"2021","journal-title":"CNS Spectr"},{"issue":"7","key":"10.1016\/j.chc.2023.02.006_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/070674378703200712","article-title":"Alprazolam effects in children with anxiety disorders","volume":"32","author":"Simeon","year":"1987","journal-title":"Can J Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004583-199201000-00006","article-title":"Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders","volume":"31","author":"Simeon","year":"1992","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004583-199403000-00011","article-title":"Clonazepam in childhood anxiety disorders","volume":"33","author":"Graae","year":"1994","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2023.02.006_bib33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-199009000-00016","article-title":"Comparative studies of pharmacotherapy for school refusal","volume":"29","author":"Bernstein","year":"1990","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/cap.2017.0060","article-title":"Buspirone in children and adolescents with anxiety: a review and bayesian analysis of abandoned randomized controlled trials","volume":"28","author":"Strawn","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0193-953X(18)30257-0","article-title":"The pharmacotherapy of anxiety disorders in children and adolescents","volume":"15","author":"Kutcher","year":"1992","journal-title":"Psychiatr Clin North Am"},{"issue":"12","key":"10.1016\/j.chc.2023.02.006_bib36","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/00912700122012823","article-title":"Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults","volume":"41","author":"Salazar","year":"2001","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/cap.2016.0132","article-title":"Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial","volume":"27","author":"Strawn","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.2008.0080","article-title":"Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Sallee","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/archpsyc.1971.01750150012002","article-title":"Controlled imipramine treatment of school phobia","volume":"25","author":"Gittelman-Klein","year":"1971","journal-title":"Arch Gen Psychiatr"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004583-199201000-00005","article-title":"Imipramine treatment of children with separation anxiety disorder","volume":"31","author":"Klein","year":"1992","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00004583-200003000-00008","article-title":"Imipramine plus cognitive-behavioral therapy in the treatment of school refusal","volume":"39","author":"Bernstein","year":"2000","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2023.02.006_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1037\/0022-006X.62.1.100","article-title":"Treating anxiety disorders in children: results of a randomized clinical trial","volume":"62","author":"Kendall","year":"1994","journal-title":"J\u00a0Consult Clin Psychol"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1037\/0022-006X.65.3.366","article-title":"Therapy for youths with anxiety disorders: a second randomized clinical trial","volume":"65","author":"Kendall","year":"1997","journal-title":"J\u00a0Consult Clin Psychol"},{"issue":"2","key":"10.1016\/j.chc.2023.02.006_bib44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1037\/0022-006X.64.2.333","article-title":"Family treatment of childhood anxiety: a controlled trial","volume":"64","author":"Barrett","year":"1996","journal-title":"J\u00a0Consult Clin Psychol"},{"key":"10.1016\/j.chc.2023.02.006_bib45","first-page":"1","article-title":"Cognitive behavioural therapy for anxiety disorders in children and adolescents","volume":"4","author":"James","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.chc.2023.02.006_bib46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaac.2018.03.017","article-title":"Results from the child\/adolescent anxiety multimodal extended long-term study (CAMELS): primary anxiety outcomes","volume":"57","author":"Ginsburg","year":"2018","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2023.02.006_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.chi.0000246070.23695.06","article-title":"Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders","volume":"46","author":"Connolly","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2023.02.006_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/da.22329","article-title":"Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis","volume":"32","author":"Strawn","year":"2015","journal-title":"Depress Anxiety"},{"issue":"11","key":"10.1016\/j.chc.2023.02.006_bib49","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jaac.2019.10.013","article-title":"Antidepressant tolerability in pediatric anxiety and obsessive-compulsive disorders: a bayesian hierarchical modeling meta-analysis","volume":"59","author":"Mills","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2023.02.006_bib50","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/cap.2018.0160","article-title":"CYP2C19-guided escitalopram and sertraline dosing in pediatric patients: a pharmacokinetic modeling study","volume":"29","author":"Strawn","year":"2019","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2023.02.006_bib51","article-title":"CYP2C19 metabolizer status predicts sertraline and escitalopram pharmacokinetics in children and adolescents","author":"Poweleit","year":"2021","journal-title":"Paper presented at: neuropsychopharmacology"},{"key":"10.1016\/j.chc.2023.02.006_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphar.2019.00099","article-title":"Influence of CYP2C19 metabolizer status on escitalopram\/citalopram tolerability and response in youth with anxiety and depressive disorders","author":"Aldrich","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.chc.2023.02.006_bib53","unstructured":"Genetics ISoP. Genetic Testing and Psychiatric Disorders. A Statement from the International Society of Psychiatric Genetics 2019. Available at: https:\/\/ispg.net\/genetic-testing-statement\/. Accessed March 17, 2023."},{"issue":"6","key":"10.1016\/j.chc.2023.02.006_bib54","first-page":"660","article-title":"Thoughtful clinical use of pharmacogenetics in child and adolescent psychopharmacology","volume":"60","author":"Ramsey","year":"2021","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2023.02.006_bib55","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1016\/j.jaac.2022.07.645","article-title":"16.1 principles of pharmacogenetic testing in children and adolescents","volume":"61","author":"Strawn","year":"2022","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"}],"container-title":["Child and Adolescent Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499323000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499323000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:51:59Z","timestamp":1761000719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056499323000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1056499323000172"],"URL":"https:\/\/doi.org\/10.1016\/j.chc.2023.02.006","relation":{},"ISSN":["1056-4993"],"issn-type":[{"value":"1056-4993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Pharmacotherapy for Pediatric Anxiety Disorders","name":"articletitle","label":"Article Title"},{"value":"Child and Adolescent Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chc.2023.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}